Clinical Trial Update: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 study evaluating CLN-619 alone and in combination with pembrolizumab in advanced solid tumors, including non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CLN-619
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Cullinan Therapeutics Inc. | Conditions: Advanced Solid Tumor, NSCLC | Phase 1 | Status: ACTIVE_NOT_RECRUITING